Drugmakers Boost US Presence Amid Tariff Threats
Global drugmakers are boosting U.S. investments and stockpiling inventory to avoid 100% tariffs. Firms like Pfizer and Eli Lilly are expanding domestic plants.
Xurve View
Insights:
Xurve View
Global pharmaceutical manufacturers are significantly increasing their industrial footprint in the United States as the incoming Trump administration weighs a 100% tariff on imported branded and patented medicines. To avoid these penalties, major industry players are fast-tracking domestic production facilities, stockpiling inventory, and negotiating direct agreements with the federal government.
